A consortium comprising HBM BioVentures, SV Life Sciences, Clarus Ventures, BioMedinvest, Novartis Bioventures and VI Partners has agreed to sell ESBATech AG to listed eye care company Alcon, for an initial cash purchase price of $150m.
Second vehicle will be larger than its predecessor, which closed on €843m in March 2010
Dieter von Holtzbrinck Ventures (DvH Ventures) has announced the launch of its first Digital Health fund, which has held a first close on €60m.
Sale ends a three-year holding period for Astorg, which acquired a 75% stake in the company from Xenon PE
Acquisition of Germany-based x-ray equipment and software was backed by senior debt from ApoBank